The antibodies against 5-bromo-2′-deoxyuridine specifically recognize trifluridine incorporated into DNA
Open Access
- 3 May 2016
- journal article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 6 (1), 25286
- https://doi.org/10.1038/srep25286
Abstract
Trifluridine (FTD) is a key component of the novel oral antitumor drug TAS-102 (also named TFTD), which consists of FTD and a thymidine phosphorylase inhibitor. FTD is supposed to exert its cytotoxicity via massive misincorporation into DNA, but the underlying mechanism of FTD incorporation into DNA and its correlation with cytotoxicity are not fully understood. The present study shows that several antibodies against 5-bromo-2′-deoxyuridine (BrdU) specifically cross-react with FTD, either anchored to bovine serum albumin or incorporated into DNA. These antibodies are useful for several biological applications, such as fluorescence-activated cell sorting, fluorescent immunostaining and immunogold detection for electron microscopy. These techniques confirmed that FTD is mainly incorporated in the nucleus during S phase in a concentration-dependent manner. In addition, FTD was also detected by immunohistochemical staining in paraffin-embedded HCT-116 xenograft tumors after intraperitoneal administration of FTD. Intriguingly, FTD was hardly detected in surrounding matrices, which consisted of fibroblasts with marginal expression of the nucleoside transporter genes SLC29A1 and SLC29A2. Thus, applications using anti-BrdU antibodies will provide powerful tools to unveil the underlying mechanism of FTD action and to predict or evaluate the efficacy and adverse effects of TAS-102 clinically.This publication has 29 references indexed in Scilit:
- New Challenges and Inspired Answers for Anticancer Drug Discovery and DevelopmentJapanese Journal of Clinical Oncology, 2013
- Thymidine Analogues for Tracking DNA SynthesisMolecules, 2011
- Replication Labeling with Halogenated Thymidine AnalogsCurrent Protocols in Cell Biology, 2007
- Phase I study to determine the safety and pharmacokinetics of oral administration of TAS‐102 in patients with solid tumorsCancer, 2006
- The spatio-temporal organization of DNA replication sites is identical in primary, immortalized and transformed mammalian cellsJournal of Cell Science, 2002
- Replicon Clusters Are Stable Units of Chromosome Structure: Evidence That Nuclear Organization Contributes to the Efficient Activation and Propagation of S Phase in Human CellsThe Journal of cell biology, 1998
- Improved high-affinity monoclonal antibody to lododeoxyuridineCytometry, 1986
- An immunofluorescence method for monitoring DNA synthesis by flow cytometryCytometry, 1981
- Deoxyribonucleic acid replication in single cells and chromosomes by immunologic techniques.Journal of Histochemistry & Cytochemistry, 1976
- The use of antibody specific for bromodeoxyuridine for the immunofluorescent determination of DNA replication in single cells and chromosomesExperimental Cell Research, 1975